Legorreta Pablo G. — SEC insider filings

SEC reporting owner CIK 1507678. 32 insider filings on record with FilingPulse; latest filed 2026-11-06.

Transaction summary — filings shown

Covers all 32 filings on record, filed 2021-05-11 to 2026-11-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
PROKIDNEY CORP. (PROK)Director, 10% owner101 leg · 22,617,909 sh · $54,735,340—23
Epizyme, Inc. (EPZM)Director, 10% owner41 leg · 22,666,667 sh · $34,000,000—7
Royalty Pharma plc (RPRX)CEO, Chairman of the Board, Director186 legs · 600,000 sh · $19,310,880—36

Insider filings — Legorreta Pablo G.

FiledFormIssuerReported transactionsSource
2026-11-064Royalty Pharma plc (RPRX)Grant/award (A): 42,209 @ $0EDGAR
2026-08-074Royalty Pharma plc (RPRX)Grant/award (A): 65,216 @ $0 · Gift (G): 30,000 (derivative) @ $0EDGAR
2026-05-294PROKIDNEY CORP. (PROK)Grant/award (A): 135,000 (derivative) @ $0EDGAR
2026-05-084Royalty Pharma plc (RPRX)Grant/award (A): 143,821 @ $0EDGAR
2026-02-134Royalty Pharma plc (RPRX)Grant/award (A): 157,828 @ $0EDGAR
2025-11-074Royalty Pharma plc (RPRX)Grant/award (A): 36,559 @ $0EDGAR
2025-08-084Royalty Pharma plc (RPRX)Grant/award (A): 21,901 @ $0 · Gift (G): 60,000 (derivative) @ $0EDGAR
2025-06-054PROKIDNEY CORP. (PROK)
jointly with Tolerantia, LLC
Conversion (C): 3,823,996 @ $0 · Other (J): 3,823,996 @ $0 · Conversion (C): 3,823,996 (derivative) @ $0 · Conversion (C): 3,823,996 (derivative) @ $0EDGAR
2025-06-024PROKIDNEY CORP. (PROK)Grant/award (A): 125,862 (derivative) @ $0EDGAR
2025-05-204Royalty Pharma plc (RPRX)Other (J): 530,348 @ $0 · Grant/award (A): 13,356,742 (derivative) @ $0 · Other (J): 857,138 (derivative) @ $0EDGAR
2025-05-144Royalty Pharma plc (RPRX)Gift (G): 867,180 (derivative) @ $0 · Gift (G): 867,180 (derivative) @ $0EDGAR
2025-05-094Royalty Pharma plc (RPRX)Grant/award (A): 288,352 @ $0EDGAR
2025-02-064PROKIDNEY CORP. (PROK)
jointly with Tolerantia, LLC
Conversion (C): 532,535 @ $0 · Other (J): 532,535 @ $0 · Conversion (C): 532,535 (derivative) @ $0 · Conversion (C): 532,535 (derivative) @ $0EDGAR
2024-06-144PROKIDNEY CORP. (PROK)
jointly with Tolerantia, LLC
Purchase (P): 22,617,909 @ $2.42EDGAR
2024-06-034PROKIDNEY CORP. (PROK)Grant/award (A): 62,558 (derivative) @ $0EDGAR
2024-02-064PROKIDNEY CORP. (PROK)
jointly with Tolerantia, LLC
Conversion (C): 748,952 @ $0 · Other (J): 748,952 @ $0 · Conversion (C): 748,952 (derivative) @ $0 · Conversion (C): 748,952 (derivative) @ $0EDGAR
2023-11-164Royalty Pharma plc (RPRX)Gift (G): 292,190.49 @ $0 · Other (J): 383,000 @ $0EDGAR
2023-11-014PROKIDNEY CORP. (PROK)
jointly with Tolerantia, LLC
Conversion (C): 5,289,055 @ $0 · Other (J): 5,289,055 @ $0 · Conversion (C): 5,289,055 (derivative) @ $0 · Conversion (C): 5,289,055 (derivative) @ $0EDGAR
2023-07-034PROKIDNEY CORP. (PROK)Grant/award (A): 48,128 (derivative) @ $0EDGAR
2023-06-284Royalty Pharma plc (RPRX)Purchase (P): 130,000 @ $29.51EDGAR
2023-06-134Royalty Pharma plc (RPRX)Purchase (P): 45,000 @ $33.00 · Purchase (P): 45,000 @ $32.78EDGAR
2023-05-244Royalty Pharma plc (RPRX)Purchase (P): 150,000 @ $32.25EDGAR
2023-05-174Royalty Pharma plc (RPRX)Purchase (P): 160,388 @ $33.57 · Purchase (P): 69,612 @ $32.94EDGAR
2023-05-154Royalty Pharma plc (RPRX)Gift (G): 10,269 (derivative) @ $0 · Gift (G): 10,269 (derivative) @ $0EDGAR
2022-08-164Epizyme, Inc. (EPZM)
jointly with RP Management, LLC, RPI Finance Trust, Royalty Pharma Investments 2019 ICAV
Code (U): 31,933,334 · Disposition to issuer (D): 8,060 (derivative) @ $0 · Disposition to issuer (D): 8,994 (derivative) @ $0EDGAR
2022-07-134PROKIDNEY CORP. (PROK)
jointly with Tolerantia, LLC
Grant/award (A): 94,677,968 (derivative) @ $0 · Grant/award (A): 94,677,968 (derivative) @ $0 · Grant/award (A): 10,500,000 (derivative) @ $0EDGAR
2022-05-194Epizyme, Inc. (EPZM)
jointly with RP Management, LLC, RPI Finance Trust, Royalty Pharma Investments 2019 ICAV
Grant/award (A): 41,006 (derivative) @ $0.56 · Grant/award (A): 8,994 (derivative) @ $0EDGAR
2022-04-154/ARoyalty Pharma plc (RPRX)Grant/award (A): 1,719,074 (derivative) @ $0EDGAR
2022-04-154Royalty Pharma plc (RPRX)Conversion (C): 493,750 @ $0 · Conversion (C): 428,420 @ $0 · Other (J): 462,031 @ $0 · Other (J): 350,000 @ $0 · Conversion (C): 49,375 (derivative) @ $0 · Conversion (C): 49,375 (derivative) @ $0 · +7 moreEDGAR
2022-02-014Epizyme, Inc. (EPZM)
jointly with RP Management, LLC, RPI Finance Trust
Purchase (P): 22,666,667 @ $1.50EDGAR
2021-06-154Epizyme, Inc. (EPZM)
jointly with RP Management, LLC, RPI Finance Trust
Grant/award (A): 40,559 (derivative) @ $8.53 · Grant/award (A): 8,060 (derivative) @ $0EDGAR
2021-05-114Royalty Pharma plc (RPRX)Conversion (C): 1,040,410 @ $0 · Conversion (C): 1,284,590 @ $0 · Conversion (C): 104,041 (derivative) @ $0 · Conversion (C): 128,459 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-03-08 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1507678 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs